Ergomed — FY2017 Earnings Presentation
22 slides from Ergomed's earnings presentation, April 2018
Slide 1: Preliminary Results 2017
TRANSFORMING DRUG DEVELOPMENT Preliminary Results 2017 April 2018 www.ergomedplc.com 1
Slide 2: Disclaimer
DISCLAIMER The information contained in this confidential document (“Presentation”) has been prepared by Ergomed plc (the “Company”). It has not been independently verified and is subject to material updating, revision and further amendment. This Presentation has not been approved by an authorised p
Slide 3: 2017 Prelims: Financial Highlights
2017 PRELIMS: FINANCIAL HIGHLIGHTS Another year of strong growth Net service Total Gross EBITDA revenue up revenue up profit up (adjusted) Cash at bank at 36% to 21% to 22% to before R&D 31 Dec 2017 £39.6 million £47.6 million £14.6 million £5.5 million £3.2 million (2016: £29.2 million) (2016: £39.
Slide 4: 2017 Operational Highlights
2017 OPERATIONAL HIGHLIGHTS Strong delivery and business outlook £54 million £88 million €5.7 million First licensing Multiple deal product of new contracts of contracted acquisition of for Haemostatix milestones, won through backlog at PSR Group products for including December 2017 31 December or u
Slide 5: Services – Fast-Growing
SERVICES – FAST-GROWING Continuing to out-pace the market with global solutions Drug Safety & Clinical Research Medical Information +68% GROWTH +9% GROWTH Services £17.4m Outsourced PV £39.6m CRO industry growth industry growth Net service revenue +7.5%2 +18%1 £22.2m 1 Source: Global Market Insights
Slide 6: Focus on Specialised Services to Pharma
FOCUS ON SPECIALISED SERVICES TO PHARMA 20+ years of profitable growth COMPLETING THE DEVELOPMENT OUR MISSION CIRCLE Building a profitable services business with a focus on ....... Service cycle global leadership in pharmacovigilance and orphan drug development by 2020 Drug Safety and Medical Inform
Slide 7: Drug Safety & Medical Information
DRUG SAFETY & MEDICAL INFORMATION Critical business enabler in both developed and emerging markets Pharmaco- Pharmacovigilance vigilance market The science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other drug related problem. (WHO,
Slide 8: Pharmacovigilance & Medical Information Services
PHARMACOVIGILANCE & MEDICAL INFORMATION SERVICES Business enabler for biotech and pharma PV: Ensuring drugs get on the market quicker & stay there, even if benefit-risk profile is challenged by regulators. £22.5m Medical Information: Net service revenue Multi-lingual call centres for enquiries of he
Slide 9: Drug Safety & Medical Information Services
DRUG SAFETY & MEDICAL INFORMATION SERVICES Vision 2020: world’s leading pharmacovigilance provider Formation of Launch of IPO on AIM Acquisition of Acquisition PrimeVigilance in Medical Sound Opinion – of PharmInvent – expert UK Information UK MI company regulatory and PV Company 2008 2013 2014 2015
Slide 10: Transforming Pharmacovigilance with Intelligent Automation
TRANSFORMING PHARMACOVIGILANCE WITH INTELLIGENT AUTOMATION PrimeVigilance assumptions • By 2020, automation is likely to reduce manual case- processing efforts by over 80% and decrease costs by at least 50%. • Improving the accuracy, quality, and consistency, creating better audit trails faster, and
Slide 11: Clinical Research Services
CLINICAL RESEARCH SERVICES Efficient management and control of complex trial protocols In its Clinical Research Services division, Ergomed Focusing on patient recruitment with undertakes on behalf of our clients all facets of clinical trial efficient management and control of management and executio
Slide 12: Clinical Research Services: Orphan Drug Focus
CLINICAL RESEARCH SERVICES Focus: global leadership in Orphan Drug development Orphan Drug trials are complicated by the nature and types of therapy and patient recruitment. Specialist knowledge combined with tailored recruitment • Leading Orphan Drug CRO in Europe and site management required for o
Slide 13: PeproStat Phase II Results
PEPROSTAT PHASE II RESULTS Primary endpoint met: 1.6 minutes (p<0.004) reduction in TTH RANDOMISED, BLINDED, PARALLEL-GROUP, MULTICENTRE CONTROLLED CLINICAL TRIAL Three surgery types: open liver/soft tissue, vascular, spine Time to haemostatis n Mean Median PeproStat + gelatin sponge 110 4.2 3.0 All
Slide 14: Co-Development Update
CO-DEVELOPMENT UPDATE Multiple milestones in 2017 PARTNERSHIP STATUS UPDATE • Successful Phase II data reported February 2017 Lorediplon / • Ferrer seeking commercial partner(s) insomnia • Phase III data announced May 2017 Zoptrex™ / • Zoptrex did not show treatment benefit over doxorubicin endometr
Slide 15: Profit and Loss Account
PROFIT AND LOSS ACCOUNT £000s FY 2017 FY 2016 Net service revenue 39,645 29,224 Licence revenue 370 - Reimbursement revenue 7,609 10,009 REVENUE 47,624 39,233 GROSS PROFIT 14,621 11,994 Administrative expenses (15,954) (10,822) Other administrative expenses (9,725) (8,323) Amortisation of acquired f
Slide 16: Balance Sheet
BALANCE SHEET £000s 31 December 2017 31 December 2016 Goodwill 15,269 12,285 Intangibles 20,229 19,842 Other non-current assets 3,445 2,436 NON-CURRENT ASSETS 38,943 34,563 Trade and other receivables 19,250 14,958 Other current assets 502 240 Cash and cash equivalents 3,218 4,424 CURRENT ASSETS 22,
Slide 17: Trade and Other Receivables
TRADE AND OTHER RECEIVABLES £000s 31 December 2017 31 December 2016 Trade debtors 13,390 9,540 Other receivables 1,702 1,025 Prepayments 733 841 Accrued income 2,443 2,538 Corp. tax receivable 982 1,014 TOTAL 19,250 14,958 DSO (incl. acquisitions) 92 days 89 days DSO (excl. acquisitions) 89 days 82
Slide 18: Strategy for Accelerated Growth
STRATEGY FOR ACCELERATED GROWTH 2017 DELIVERY STRATEGY • Focus on our services growth ORGANIC 30%+ top line growth • Outpace the market GROWTH • Build out global infrastructure • Add specialist skills ACQUISITIONS • Goal is global leadership in: • Pharmacovigilance • Orphan Drug development DEVELOPM
Slide 19: Questions?
QUESTIONS? www.ergomedplc.com | 19
Slide 20: Site Management Model
SITE MANAGEMENT MODEL Significantly Increases Study Performance • Large Phase III Head & Neck Cancer rescue Monthly Enrolment Chart study • Urgent assistance was required to open sites and 45 enroll patients 40 • Ergomed’s Study Physician program significantly increased study progress: 35 560% inc
Slide 21: Study Physician Group
STUDY PHYSICIAN GROUP Case Study • Study Physician Support model was used to # of patients enrolled prior to and after Study support a different CRO’s enrollment process Physician involvement • Advanced NSCL Adenocarcinoma study was lagging recruitment goals • In the 10 months that Ergomed was invol
Slide 22: EU Good Pharmacovigilance Practice (since June 2012)
EU GOOD PHARMACOVIGILANCE PRACTICE (SINCE JUNE 2012) www.ergomedplc.com | 22